The biotech firm reported a larger adjusted net loss of $2.1 million for Q1, up from $1.3 million a year earlier.
Purple Biotech reported a first-quarter GAAP loss of $0.09 per share, reflecting a deeper financial deficit. The company’s adjusted net loss widened to $2.1 million from $1.3 million in the same period last year, a $0.8 million increase.
Cash reserves stood at $6.4 million as of March 31, 2026, which management expects will extend the company’s runway into 2027. The results underscore ongoing challenges in narrowing losses amid operational expenses.
No immediate market reaction was disclosed in the release.